

Patrick A Baeuerle

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11190302/patrick-a-baeuerle-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

158
papers

27,112
citations

83
h-index

160
g-index

160
ext. papers

28,658
ext. citations

10.1
avg, IF

6.87
L-index

#	Paper	IF	Citations
158	Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. <i>Cell</i> , 1988 , 53, 211-7	56.2	1152
157	Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). <i>Free Radical Research Communications</i> , 1992 , 17, 221-37		1141
156	Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. <i>Nature</i> , 1993 , 365, 182-5	50.4	1061
155	The DNA binding subunit of NF-kappa B is identical to factor KBF1 and homologous to the rel oncogene product. <i>Cell</i> , 1990 , 62, 1007-18	56.2	902
154	Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. <i>Science</i> , 2008 , 321, 974-7	33.3	802
153	Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2493-8	2.2	714
152	Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. <i>Cell</i> , 1996 , 86, 787-98	56.2	643
151	Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. <i>Gastroenterology</i> , 1998 , 115, 357-69	13.3	592
150	Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. <i>Free Radical Biology and Medicine</i> , 2000 , 28, 1317-27	7.8	566
149	Nuclear signalling by tumour-associated antigen EpCAM. <i>Nature Cell Biology</i> , 2009 , 11, 162-71	23.4	522
148	NF-B as a Frequent Target for Immunosuppressive and Anti-Inflammatory Molecules**This article was accepted for publication on 27 September 1996.. <i>Advances in Immunology</i> , 1997 , 111-137	5.6	457
147	Activate NF-kappa B or die?. <i>Current Biology</i> , 1997 , 7, R94-6	6.3	450
146	A role for oxygen radicals as second messengers. <i>Trends in Cell Biology</i> , 1991 , 1, 39-42	18.3	435
145	Nuclear factor kappa B, a mediator of lipopolysaccharide effects. <i>Immunobiology</i> , 1993 , 187, 233-56	3.4	431
144	Bispecific T-cell engaging antibodies for cancer therapy. <i>Cancer Research</i> , 2009 , 69, 4941-4	10.1	424
143	Purified human I kappa B can rapidly dissociate the complex of the NF-kappa B transcription factor with its cognate DNA. <i>Cell</i> , 1990 , 61, 255-65	56.2	412
142	IkappaB-NF-kappaB structures: at the interface of inflammation control. <i>Cell</i> , 1998 , 95, 729-31	56.2	409

141	The emerging role of EpCAM in cancer and stem cell signaling. <i>Cancer Research</i> , 2009 , 69, 5627-9	10.1	405
140	The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. <i>Chemistry and Biology</i> , 1995 , 2, 13-22		399
139	The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1991 , 1072, 63-80	11.2	398
138	Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i> , 2012 , 120, 5185-7	2.2	389
137	Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-kappa B subunit. <i>Cell</i> , 1992 , 68, 1121-33	56.2	370
136	Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. <i>Blood</i> , 2012 , 119, 6226-33	2.2	328
135	The ER-overload response: activation of NF-kappa B. <i>Trends in Biochemical Sciences</i> , 1997 , 22, 63-7	10.3	297
134	IKAP is a scaffold protein of the IkappaB kinase complex. <i>Nature</i> , 1998 , 395, 292-6	50.4	275
133	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1104-11	2.2	273
132	Regulation of the transcription factors NF-kappa B and AP-1 by redox changes. <i>Chemico-Biological Interactions</i> , 1994 , 91, 91-100	5	259
131	Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle?. <i>Current Biology</i> , 1998 , 8, R19-22	6.3	256
130	Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. <i>Biochemical Pharmacology</i> , 1995 , 50, 735-41	6	253
129	Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. <i>International Journal of Cancer</i> , 2005 , 115, 98-104	7.5	247
128	Combined transcriptome and genome analysis of single micrometastatic cells. <i>Nature Biotechnology</i> , 2002 , 20, 387-92	44.5	245
127	Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. <i>International Journal of Cancer</i> , 2002 , 100, 690-7	7.5	240
126	Oxygen and the control of gene expression. <i>BioEssays</i> , 1994 , 16, 497-502	4.1	234
125	Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. <i>Molecular Immunology</i> , 2006 , 43, 763-71	4.3	232
124	Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. <i>Methods</i> , 1997 , 11, 301-12	4.6	231

123	Blinatumomab: a historical perspective. <i>Pharmacology & Therapeutics</i> , 2012 , 136, 334-42	13.9	221
122	MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. <i>Molecular Immunology</i> , 2006 , 43, 1129-43	4.3	198
121	BiTEs: bispecific antibody constructs with unique anti-tumor activity. <i>Drug Discovery Today</i> , 2005 , 10, 1237-44	8.8	192
120	Brain synapses contain inducible forms of the transcription factor NF-kappa B. <i>Mechanisms of Development</i> , 1993 , 43, 135-47	1.7	189
119	Sex reversal by loss of the C-terminal transactivation domain of human SOX9. <i>Nature Genetics</i> , 1996 , 13, 230-2	36.3	182
118	Hydrogen peroxide as a potent activator of T lymphocyte functions. <i>European Journal of Immunology</i> , 1995 , 25, 159-65	6.1	178
117	Activation of NF-kappa B by ER stress requires both Ca ²⁺ and reactive oxygen intermediates as messengers. <i>FEBS Letters</i> , 1996 , 392, 129-36	3.8	174
116	Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 103, 483-8	4.9	164
115	T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. <i>Journal of Immunology</i> , 2003 , 170, 4397-402	5.3	160
114	Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-kappa B. <i>Journal of Biological Chemistry</i> , 1995 , 270, 27136-42	5.4	147
113	The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. <i>FEBS Journal</i> , 1995 , 234, 632-40		143
112	Transactivation domain 2 (TA2) of p65 NF-kappa B. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. <i>Journal of Biological Chemistry</i> , 1995 , 270, 15576-84	5.4	141
111	Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. <i>Experimental Cell Research</i> , 2011 , 317, 1255-60	4.2	140
110	Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. <i>Immunobiology</i> , 2009 , 214, 441-53	3.4	140
109	Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. <i>Journal of Immunotherapy</i> , 2007 , 30, 798-807	5	139
108	Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators. <i>Journal of Biological Chemistry</i> , 1995 , 270, 7219-26	5.4	135
107	Targeting T cells to tumor cells using bispecific antibodies. <i>Current Opinion in Chemical Biology</i> , 2013 , 17, 385-92	9.7	134
106	Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-kappa B. <i>Methods in Enzymology</i> , 1994 , 234, 151-63	1.7	134

105	CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. <i>Blood</i> , 2014 , 123, 356-65	2.2	132
104	A revival of bispecific antibodies. <i>Trends in Biotechnology</i> , 2004 , 22, 238-44	15.1	129
103	Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1197-209	7.4	125
102	Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 1901-9	9.4	117
101	Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. <i>Journal of Biological Chemistry</i> , 1997 , 272, 23435-9	5.4	116
100	Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. <i>Cancer Research</i> , 2005 , 65, 2882-9	10.1	116
99	Potential involvement of the transcription factor NF-kappa B in neurological disorders. <i>Molecular Aspects of Medicine</i> , 1993 , 14, 171-90	16.7	116
98	T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 12605-10	11.5	113
97	The NF-kappa B transcription factor induces DNA bending which is modulated by its 65-kD subunit. <i>Nucleic Acids Research</i> , 1990 , 18, 6497-502	20.1	112
96	High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. <i>Molecular Immunology</i> , 2006 , 43, 1183-93	4.3	109
95	Proteins controlling the nuclear uptake of NF-kappa B, Rel and dorsal. <i>Trends in Cell Biology</i> , 1991 , 1, 130-7	18.3	107
94	On the abundance of EpCAM on cancer stem cells. <i>Nature Reviews Cancer</i> , 2009 , 9, 143; author reply 143	31.3	105
93	The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1551-63	7.4	104
92	Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. <i>Circulation</i> , 2001 , 103, 1396-402	16.7	103
91	Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. <i>European Journal of Immunology</i> , 1996 , 26, 2119-26	6.1	103
90	The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. <i>Journal of Biological Chemistry</i> , 2000 , 275, 29779-87	5.4	99
89	EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. <i>Clinical Cancer Research</i> , 2012 , 18, 465-74	12.9	96
88	Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2664-73	6.1	95

87	Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. <i>Journal of Biological Chemistry</i> , 1995 , 270, 26419-32	5.4	95
86	Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1549-57	6.1	94
85	Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. <i>Leukemia and Lymphoma</i> , 2009 , 50, 886-91	1.9	92
84	Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1. <i>FEBS Journal</i> , 1997 , 244, 45-52		92
83	Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. <i>Journal of Biological Chemistry</i> , 1997 , 272, 22278-84	5.4	88
82	Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. <i>Molecular Cell</i> , 2001 , 7, 1059-69	17.6	85
81	BiTE: Teaching antibodies to engage T-cells for cancer therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2009 , 11, 22-30		85
80	T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 503-14	7.4	84
79	Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. <i>Cancer Cell International</i> , 2010 , 10, 44	6.4	83
78	CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. <i>Molecular Immunology</i> , 2007 , 44, 1935-43	4.3	83
77	Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages. <i>Hepatology</i> , 1995 , 22, 613-9	11.2	83
76	A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. <i>Journal of Immunology</i> , 2003 , 170, 5089-94	5.3	78
75	Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. <i>Cancer Research</i> , 2007 , 67, 3927-35	10.1	77
74	In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. <i>International Journal of Cancer</i> , 2002 , 100, 101-10	7.5	75
73	Multi-step activation of NF-kappa B/Rel transcription factors. <i>Immunobiology</i> , 1995 , 193, 116-27	3.4	69
72	CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. <i>MAbs</i> , 2014 , 6, 1571-84	6.6	63
71	Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. <i>Journal of Immunotherapy</i> , 2009 , 32, 341-52	5	63
70	Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. <i>Cancer Research</i> , 2008 , 68, 143-51	10.1	63

69	Endoplasmicreticulum-induced signal transduction and gene expression. <i>Trends in Cell Biology</i> , 1997 , 7, 50-5	18.3	62
68	Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. <i>Leukemia Research</i> , 2009 , 33, 465-73	2.7	61
67	Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kappaB. <i>Advances in Experimental Medicine and Biology</i> , 1996 , 387, 63-8	3.6	59
66	Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. <i>PLoS ONE</i> , 2010 , 5, e13474	3.7	58
65	Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. <i>Nature Communications</i> , 2019 , 10, 2087	17.4	56
64	Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes. <i>European Journal of Immunology</i> , 2001 , 31, 1646-55	6.1	55
63	The physiology of the NF- κ B transcription factor. <i>Molecular Aspects of Cellular Regulation</i> , 1991 , 6, 423-446		55
62	Tumor necrosis factor beta (TNF-beta) induces binding of the NF-kappa B transcription factor to a high-affinity kappa B element in the TNF-beta promoter. <i>Cytokine</i> , 1990 , 2, 389-97	4	54
61	Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. <i>Journal of Immunotherapy</i> , 2009 , 32, 452-64	5.4	52
60	Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?. <i>Cancer and Metastasis Reviews</i> , 2020 , 39, 969-987	9.6	51
59	Epithelial tight junction proteins as potential antibody targets for pancreatic carcinoma therapy. <i>Cancer Immunology, Immunotherapy</i> , 2005 , 54, 431-45	7.4	47
58	Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties. <i>Molecular Pharmacology</i> , 2004 , 65, 880-9	4.3	46
57	Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 785-96	7.4	44
56	Bispecific T cell engager (BiTE) antibody constructs can mediate bystander tumor cell killing. <i>PLoS ONE</i> , 2017 , 12, e0183390	3.7	43
55	Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. <i>Experimental Hematology and Oncology</i> , 2017 , 6, 14	7.8	43
54	Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. <i>FASEB Journal</i> , 2005 , 19, 246-8	0.9	43
53	Appearance of apparently ubiquitin-conjugated I kappa B-alpha during its phosphorylation-induced degradation in intact cells. <i>Journal of Cell Science</i> , 1995 , 19, 79-84	5.3	42
52	A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. <i>European Journal of Cancer</i> , 2006 , 42, 2530-8	7.5	40

51	The activity of Γ cells against paediatric liver tumour cells and spheroids in cell culture. <i>Liver International</i> , 2013 , 33, 127-36	7.9	33
50	Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. <i>Journal of Immunotherapy</i> , 2011 , 34, 597-605	5	33
49	Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 95-109	7.4	29
48	A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. <i>Molecular Immunology</i> , 2007 , 44, 916-25	4.3	28
47	Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. <i>Urologia Internationalis</i> , 2010 , 85, 386-95	1.9	26
46	Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. <i>International Journal of Cancer</i> , 2003 , 105, 241-8	7.5	25
45	Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. <i>MABs</i> , 2011 , 3, 31-7	6.6	22
44	Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. <i>International Immunology</i> , 2003 , 15, 789-96	4.9	22
43	Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003 , 129, 341-8	4.9	21
42	The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. <i>PLoS ONE</i> , 2012 , 7, e36412	3.7	20
41	Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs. <i>Journal of Virology</i> , 2018 , 92,	6.6	19
40	Bispecific antibodies for polyclonal T-cell engagement. <i>Current Opinion in Molecular Therapeutics</i> , 2003 , 5, 413-9		19
39	Structural analysis, expression, and chromosomal localization of the mouse ikba gene. <i>Immunogenetics</i> , 1999 , 49, 395-403	3.2	18
38	trans-Activation of the HIV type 1 promoter by 7,8-dihydroneopterin in vitro. <i>AIDS Research and Human Retroviruses</i> , 1997 , 13, 173-8	1.6	17
37	Highly efficient antigen targeting to M-DC8+ dendritic cells via Fc γ RIII/CD16-specific antibody conjugates. <i>International Immunology</i> , 2005 , 17, 539-47	4.9	17
36	Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. <i>PLoS ONE</i> , 2015 , 10, e0141669	3.7	16
35	Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.. <i>Blood</i> , 2008 , 112, 1926-1926	2.2	15
34	Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. <i>Journal of Immunotherapy</i> , 2006 , 29, 477-88	5	14

33	Developmental and tissue-specific expression of the Q5k gene. <i>Immunogenetics</i> , 1991 , 34, 28-38	3.2	14
32	Reactive Oxygen Intermediates as Primary Signals and Second Messengers in the Activation of Transcription Factors 1997 , 239-259		12
31	Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma. <i>Current Clinical Pharmacology</i> , 2018 , 13, 55-64	2.5	12
30	Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection. <i>Antiviral Research</i> , 2017 , 141, 155-164	10.8	11
29	Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 459-68	7.4	11
28	The histidine tail of recombinant DNA binding proteins may influence the quality of interaction with DNA. <i>Analytical Biochemistry</i> , 1996 , 234, 227-30	3.1	11
27	A hydrophobic region within the adenovirus E1B 19 kDa protein is necessary for the transient inhibition of NF-κB activated by different stimuli. <i>Journal of Biological Chemistry</i> , 1996 , 271, 20392-8	5.4	10
26	Clinical experience with gene therapy and bispecific antibodies for T cell-based therapy of cancer. <i>Current Pharmaceutical Biotechnology</i> , 2012 , 13, 1399-408	2.6	9
25	Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL. <i>Blood</i> , 2008 , 112, 267-267	2.2	8
24	A new interference footprinting method for analysing simultaneously protein contacts to phosphate and guanine residues on DNA. <i>Nucleic Acids Research</i> , 1995 , 23, 1443-4	20.1	7
23	TriTACs, a Novel Class of T-Cell-Engaging Protein Constructs Designed for the Treatment of Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 109-120	6.1	7
22	Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 1452-1462	12.9	6
21	Implications of T cell receptor biology on the development of new T cell therapies for cancer. <i>Immunotherapy</i> , 2020 , 12, 89-103	3.8	5
20	Cloning of the murine relA (p65 NF-κB) gene and comparison to the human gene reveals a distinct first intron. <i>Gene</i> , 1996 , 176, 119-24	3.8	5
19	Myocardial gene expression of matched hibernating and control tissue from patients with ischemic left ventricular dysfunction. <i>Heart and Vessels</i> , 2008 , 23, 230-42	2.1	4
18	Report of a Phase II Trial of Single-Agent BiTE Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2009 , 114, 840-840	2.2	4
17	A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. <i>Molecular Immunology</i> , 2007 , 44, 1743-53	4.3	3
16	Kinases in Pro-Inflammatory Signal Transduction Pathways: New Opportunities for Drug Discovery. <i>Annual Reports in Medicinal Chemistry</i> , 1998 , 233-242	1.6	3

15	Reactive Oxygen Species as Costimulatory Signals of Cytokine-Induced NF- κ B Activation Pathways 2000 , 181-201		3
14	The Transcription Factor TCF/Elk-1. <i>Advances in Experimental Medicine and Biology</i> , 1996 , 77-84	3.6	3
13	Development of T-Cell-Engaging Bispecific Antibody Blinatumomab (Blincyto \square) for Treatment of B-Cell Malignancies 2018 , 111-130		2
12	The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. <i>Transplant Immunology</i> , 2011 , 25, 133-40	1.7	2
11	A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. <i>Molecular Immunology</i> , 2004 , 41, 511-8	4.3	2
10	Regulation of Gene Expression by Oxidative Stress. <i>Advances in Molecular and Cell Biology</i> , 1998 , 25, 15-44		2
9	Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE \square Antibody Blinatumomab.. <i>Blood</i> , 2009 , 114, 4793-4793	2.2	2
8	A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. 2022 , 10,		2
7	Resurgence of Bispecific Antibodies 2013 , 529-543		1
6	Signal Transduction from the Cytoplasm to the Cell Nucleus by NF-B/Rel Transcription Factors 1995 , 279-303		1
5	Bispecific T Cell Engager for Cancer Therapy 2011 , 273-287		1
4	Rationale for Treatment of Colorectal Cancer with EpCAM Targeting Therapeutics 179-200		
3	A bispecific single-chain antibody fusion protein for targeted depletion of autoreactive B cells via unstimulated human T lymphocytes. <i>Molecular Immunology</i> , 2004 , 41, 511-511	4.3	
2	[15]Identification of transcription factors and their target genes. <i>Methods in Molecular Genetics</i> , 1996 , 8, 278-297		
1	Passive immunotherapy by T cell \square engaging bispecific antibodies 2011 , 250-262		